# Widespread transcriptional disruption of the microRNA biogenesis machinery in brain and peripheral tissues of individuals with schizophrenia

Romain Rey, Marie-Françoise Suaud-Chagny, Jean-Michel Dorey, Jean-Raymond Teyssier, Thierry d'Amato, Thierry D'amato

► To cite this version:

Romain Rey, Marie-Françoise Suaud-Chagny, Jean-Michel Dorey, Jean-Raymond Teyssier, Thierry d'Amato, et al.. Widespread transcriptional disruption of the microRNA biogenesis machinery in brain and peripheral tissues of individuals with schizophrenia. Translational Psychiatry, 2020, 10 (1), pp.376. 10.1038/s41398-020-01052-5. hal-04962254

HAL Id: hal-04962254

https://hal.science/hal-04962254v1

Submitted on 22 Feb 2025

HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d'enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.

<figure><img src="image_1.png" /></figure>

Distributed under a Creative Commons Attribution 4.0 International License
ARTICLE

Open Access

# Widespread transcriptional disruption of the microRNA biogenesis machinery in brain and peripheral tissues of individuals with schizophrenia

Romain Rey<sup>1,2,3</sup>, Marie-Françoise Suaud-Chagny<sup>1,2</sup>, Jean-Michel Dorey<sup>2,4</sup>, Jean-Raymond Teyssier<sup>5</sup> and Thierry d'Amato<sup>1,2,3</sup>

## Abstract

In schizophrenia, altered transcription in brain and peripheral tissues may be due to altered expression of the microRNA biogenesis machinery genes. In this study, we explore the expression of these genes both at the cerebral and peripheral levels. We used *shinyGEO* application to analyze gene expression from ten Gene Expression Omnibus datasets, in order to perform differential expression analyses for eight genes encoding the microRNA biogenesis machinery. First, we compared expression of the candidate genes between control subjects and individuals with schizophrenia in postmortem cerebral samples from seven different brain regions. Then, we compared the expression of the candidate genes between control subjects and individuals with schizophrenia in three peripheral tissues. In brain and peripheral tissues of individuals with schizophrenia, we report distinct altered expression patterns of the microRNA biogenesis machinery genes. In the dorsolateral prefrontal cortex, associative striatum and cerebellum of individuals with schizophrenia, we observed an overexpression pattern of some candidate genes suggesting a heightened miRNA production in these brain regions. Additionally, mixed transcriptional abnormalities were identified in the hippocampus. Moreover, in the blood and olfactory epithelium of individuals with schizophrenia, we observed distinct aberrant transcription patterns of the candidate genes. Remarkably, in individuals with schizophrenia, we report DICER1 overexpression in the dorsolateral prefrontal cortex, hippocampus and cerebellum as well as a congruent DICER1 upregulation in the blood compartment suggesting that it may represent a peripheral marker. Transcriptional disruption of the miRNA biogenesis machinery may contribute to schizophrenia pathogenesis both in brain and peripheral tissues.

## Introduction

Schizophrenia (SZ) affects approximately 1% of the worldwide population and is responsible for a tremendous burden on society<fnref n="1" />. Subjects with SZ have a life expectancy of approximately 20 years below that of the general population<fnref n="2" />. Indeed, SZ is responsible for a dramatic increase in mortality due to suicide but also to somatic diseases (especially metabolic, cardiovascular pathology,

and cancers)<fnref n="2" />. In this respect, SZ is now considered as a systemic disease in which pathological processes take place not only at the cerebral level but also in peripheral tissues³,⁴. Despite its high prevalence and major clinical impact, SZ pathogenesis remains elusive. However, there is strong evidence that the disorder is caused by the interplay of environmental and genetic factors⁵.

New insights in schizophrenia pathogenesis have been brought by the advent of microarray technologies and more recently by transcriptome sequencing⁶⁻⁸. High-throughput gene expression studies have constantly reported the aberrant transcription of numerous genes in brain and peripheral tissues of individuals with SZ (SZ

<figure><img src="image_2.png" /></figure>

<footnote>Correspondence: Romain Rey (romain.rey@ch-le-vinatier.fr)</footnote>

<footnote n="1">¹INSERM, U1028; CNRS, UMR5292, Lyon Neuroscience Research Center, Psychiatric Disorders: from Resistance to Response Team, 69000 Lyon, France</footnote>

<footnote n="2">²University Lyon 1, 69000 Villeurbanne, France</footnote>

<footnote>Full list of author information is available at the end of the article</footnote>
individuals). To date, most findings from human post-mortem brain tissues, peripheral tissues as well as animal models have characterized differential expression of genes involved in presynaptic function, neurotransmission, signaling, myelination, neural development and migration, immune/inflammatory mechanisms, energy production, and response to oxidative stress⁶⁻⁹. Altogether, these studies indicate that SZ is associated with a global disturbance across many genes and that SZ-associated gene expression patterns correspond with functional pathways. This suggests that a complex dysregulation of gene expression may be involved in SZ pathogenesis.

To date, the majority of studies investigating the underlying mechanisms driving these transcriptional abnormalities have focused on alterations in transcription factors¹⁰, gene promoter elements¹¹, DNA methylation¹², or post-translational histone modifications¹³. However, there is now increasing evidence indicating that post-transcriptional influences on gene expression mediated by noncoding RNAs are implicated in SZ pathogenesis¹⁴⁻¹⁸. Among the different classes of noncoding RNAs, microRNAs (miRNAs) are the most widely studied. In the central nervous system, miRNAs are involved in the regulation of many essential mechanisms such as neuronal differentiation, adult neurogenesis, or synaptic plasticity¹⁹⁻²¹. While some miRNAs can regulate the expression of one specific target, others can be considered as master regulators of a process since they have the ability to control the expression levels of hundreds of genes at the same time²². Moreover, many types of miRNAs control their targets cooperatively²³. Indeed, since as much as 60% of the human protein-coding genes exhibit at least one conserved miRNA-binding site, it has been suggested that miRNAs may regulate the majority of them²⁴. Functionally, miRNAs regulate gene expression through the binding to target sites in the 3'-untranslated region of mRNAs; in this way they can either prevent mRNA translation into protein due to steric hindrance of the protein synthesis machinery or target the mRNA for enzymatic degradation²³.

Most of miRNAs are produced by the canonical miRNA biogenesis pathway. This molecular pathway relies on a miRNA biogenesis machinery (BM) constituted of several genes encoding enzymes and cofactors implicated in the transcription, nuclear processing, export and maturation of miRNAs (Fig. 1). Notably, various polymorphisms located in the miRNA BM genes have been associated with SZ risk²⁵⁻²⁸, and microarray studies in brain and peripheral tissues of SZ individuals have reported altered expression of several miRNAs suggesting a broader disruption of the miRNA BM¹⁴,¹⁸,²⁹. Previously, Beveridge et al. proposed the hypothesis that schizophrenic disorders are associated with a dysregulation of the miRNA BM in the cerebral cortex³⁰. To date, only four human studies have quantified the expression of genes coding for

the miRNA BM in postmortem brain samples³⁰,³¹ and peripheral blood¹¹,³² of SZ individuals. To our knowledge, no study has systematically explored the expression of the main miRNA BM genes in various brain regions or peripheral tissues of SZ individuals.

In this study, we used the bioinformatic application *shinyGEO* to analyze gene expression from eight Gene Expression Omnibus (GEO) datasets, in order to perform differential expression analyses for eight genes encoding the canonical miRNA BM. Firstly, we compared expression of the candidate genes between healthy controls (HC) and SZ individuals in postmortem cerebral samples from seven different brain regions. Secondly, we compared the expression of the candidate genes between HC and SZ individuals in three peripheral tissues. Thirdly, we tried to replicate our findings by analyzing the expression levels of the identified differentially expressed genes in independent validation datasets. Finally, to evaluate the neurobiological relevance of the changes identified in peripheral tissues, we compared them to those observed in brain regions.

# Material and methods

## Search and inclusion criteria of primary datasets

The GEO database is a public repository, which archives and freely distributes microarray functional genomic data from control subjects and patients suffering from various disorders, along with demographic, clinical and quality data³³. GEO datasets thus constitute a valuable resource for identifying biomarkers of diseases.

With the aim to identify altered expression of the miRNA BM genes both at the central and peripheral level in SZ individuals, we explored GEO database for datasets providing microarray expression results from SZ individuals and HC. Microarray datasets related to SZ, were searched in NCBI GEO database using the following search terms: "schizophrenia"[All Fields] AND "Homo sapiens"[porgn] AND "gse"[Filter] AND "Expression profiling by array"[Filter]. We only included datasets from original studies (i) involving brain or peripheral tissues samples from SZ individuals and HC and (ii) using the Affymetrix Human Genome U133 plus 2.0 (HG-U133_Plus_2) or Affymetrix Human Gene 1.0 ST (Human Gene 1.0 ST) or Affymetrix Human Gene 1.1 ST (Human Gene 1.1 ST) arrays. Each of these three chips can technically interrogate the expression of all the candidate genes included in the present study. Moreover, Human Gene 1.0 ST and Human Gene 1.1 ST arrays exhibit comparable detection thresholds and are highly concordant with HG-U133_Plus_2 array³⁴,³⁵.

## Included primary datasets

In this study, eight independent GEO datasets were included³⁶⁻⁴³, providing data from seven different brain
<figure><img src="image_3.png" /></figure>

regions relevant to SZ⁴⁴⁻⁴⁷ (dorsolateral prefrontal cortex (DLPFC) (BA46), anterior prefrontal cortex (BA10), parietal cortex, superior temporal cortex (BA22),

hippocampus, associative striatum, and cerebellum) and three peripheral tissues (peripheral blood mononuclear cells (PBMCs), olfactory epithelium, and skin fibroblasts).
<table><caption>**Table 1** Demographic and quality characteristics of the postmortem brain samples.</caption><thead><tr><th rowspan="2">Brain region</th><th rowspan="2">Subjects (n)</th><th colspan="2">Age (mean ± SD)</th><th colspan="2">Gender (M/F)</th><th colspan="2">Post-mortem interval (mean ± SD)</th><th colspan="2">pH (mean ± SD)</th><th colspan="2">RIN (mean ± SD)</th></tr><tr><th>Control</th><th>Schizophrenia</th><th>p-value<sup>a</sup></th><th>Control</th><th>Schizophrenia</th><th>p-value<sup>a</sup></th><th>Control</th><th>Schizophrenia</th><th>p-value<sup>a</sup></th><th>Control</th><th>Schizophrenia</th><th>p-value<sup>a</sup></th></tr></thead><tbody><tr><td colspan="14"><strong>Primary datasets</strong></td></tr><tr><td>DLPFC (BA46)</td><td>19 HC/15 SZ</td><td>48.1 ± 10.6</td><td>46 ± 8.6</td><td>0.549</td><td>10/9</td><td>7/8</td><td>1</td><td>19.5 ± 5.1</td><td>18.9 ± 6.7</td><td>0.779</td><td>6.6 ± 0.2</td><td>6.5 ± 0.4</td><td>0.551</td><td>7.8 ± 0.6</td><td>7.6 ± 0.7</td><td>0.06</td></tr><tr><td>Hippocampus</td><td>18 HC/15 SZ</td><td>48.2 ± 10.9</td><td>45.7 ± 8.8</td><td>0.493</td><td>9/9</td><td>9/6</td><td>0.728</td><td>19.4 ± 5.2</td><td>19.4 ± 7.2</td><td>0.775</td><td>6.6 ± 0.2</td><td>6.4 ± 0.3</td><td>0.358</td><td>7.4 ± 0.6</td><td>6.5 ± 0.5</td><td>0.51</td></tr><tr><td>Associative striatum</td><td>18 HC/18 SZ</td><td>48.4 ± 10.8</td><td>45 ± 8.8</td><td>0.301</td><td>10/8</td><td>10/8</td><td>1</td><td>19.8 ± 5.1</td><td>19.9 ± 7.1</td><td>0.797</td><td>6.6 ± 0.2</td><td>6.5 ± 0.4</td><td>0.337</td><td>8.2 ± 0.7</td><td>7.9 ± 0.8</td><td>0.454</td></tr><tr><td>Anterior PFC (BA10)</td><td>23 HC/28 SZ</td><td>69 ± 21.6</td><td>73.3 ± 15.2</td><td>0.411</td><td>13/10</td><td>19/9</td><td>0.561</td><td>9.9 ± 4.4</td><td>8.7 ± 7.0</td><td>0.609</td><td>6.5 ± 0.3</td><td>6.1 ± 0.2</td><td><strong>0.019</strong></td><td>-</td><td>-</td><td>-</td></tr><tr><td>Cerebellum</td><td>50 HC/44 SZ</td><td>45.8 ± 9.3</td><td>43.2 ± 9.5</td><td>0.182</td><td>31/19</td><td>32/12</td><td>0.283</td><td>-</td><td>-</td><td>-</td><td>6.5 ± 0.3</td><td>6.4 ± 0.2</td><td>0.776</td><td>-</td><td>-</td><td>-</td></tr><tr><td>Parietal cortex</td><td>50 HC/51 SZ</td><td>45.5 ± 9.0</td><td>42.6 ± 9.9</td><td>0.132</td><td>35/15</td><td>37/14</td><td>0.828</td><td>-</td><td>-</td><td>-</td><td>6.5 ± 0.3</td><td>6.4 ± 0.3</td><td>0.631</td><td>-</td><td>-</td><td>-</td></tr><tr><td>Superior temporal cortex (BA22)</td><td>19 HC/23 SZ</td><td>67.7 ± 22.2</td><td>72.2 ± 16.9</td><td>0.462</td><td>10/9</td><td>13/10</td><td>1</td><td>9.1 ± 4.3</td><td>7.1 ± 5.7</td><td>0.516</td><td>6.5 ± 0.3</td><td>6.2 ± 0.2</td><td><strong>0.002</strong></td><td>-</td><td>-</td><td>-</td></tr><tr><td colspan="14"><strong>Validation dataset</strong></td></tr><tr><td>DLPFC (BA46)</td><td>29 HC/30 SZ</td><td>44.7 ± 16.1</td><td>43.4 ± 16.9</td><td>0.759</td><td>24/5</td><td>24/6</td><td>1</td><td>40.5 ± 14</td><td>39.1 ± 11.9</td><td>0.695</td><td>6.3 ± 0.2</td><td>6.2 ± 0.2</td><td>0.199</td><td>-</td><td>-</td><td>-</td></tr></tbody></table>

The original studies from which the primary datasets were obtained are presented in Supplementary Table 1. It should be noticed that postmortem brain and peripheral tissues samples were collected from different subjects.

## Search and inclusion criteria of validation datasets

With the aim to replicate our main findings, validation datasets were searched in GEO database with identical search terms as those used in the first step of the study. For validation datasets, we selected GEO datasets from original studies (i) involving SZ individuals and HC, (ii) with samples from a brain region or a peripheral tissue in which altered transcription was observed in the primary datasets (i.e., DLPFC (BA46), associative striatum, hippocampus, cerebellum, blood compartment, and olfactory epithelium), (iii) using chips able to technically interrogate the expression of the differentially expressed genes identified in the primary datasets. Additionally, included validation datasets had to meet the following criteria: (i) a primary dataset and its validation counterpart must be derived from independent samples and (ii) the sample size of the validation dataset must be equal to or larger than that of its primary counterpart.

## Included validation datasets

At the cerebral level, we included one validation dataset<sup>48</sup> providing expression data from the DLPFC (BA46) of SZ individuals and HC. Regarding the blood compartment, one validation dataset<sup>49</sup> was included, providing expression data from the whole blood of SZ individuals and HC. The original studies from which the validation datasets were obtained are presented in Supplementary Table 2.

## Demographic characteristics and quality data

For each primary and validation GEO dataset, the quality data of the samples and the demographic characteristics of the subjects, who provided brain or peripheral tissue are summarized in Tables 1 and 2, respectively. For each GEO dataset providing data from postmortem brain samples, there was no significant difference in age, sex distribution, postmortem interval (PMI), and RNA integrity number (RIN) between the SZ individual and HC groups. For the brain pH, a significant difference was only observed in the anterior prefrontal cortex BA10 (*p* = 0.019) and in the superior temporal cortex (*p* = 0.002). For each GEO dataset providing data from peripheral tissues, there was no significant difference in age distribution between the SZ patient and HC groups. For the sex distribution, a significant difference was only observed in the whole blood (*p* = 0.0001).

## Candidate genes

The selected candidate genes code for the main components of the canonical miRNA BM: DROSHA, DGCR8,

<footnote>DLPFC dorsolateral prefrontal cortex, PFC prefrontal cortex, BA Brodmann area, RIN RNA integrity number, HC healthy controls, SZ individuals with schizophrenia.
<sup>a</sup>Unpaired t-tests and Fisher exact tests were conducted to assess group differences for continuous and discrete variables, respectively.</footnote>
<table><caption>Table 2 Demographic characteristics of the peripheral tissues samples.</caption><thead><tr><th rowspan="2">Peripheral tissue</th><th rowspan="2">Subjects (n)</th><th colspan="3">Age (mean ± SD)</th><th colspan="3">Gender (M/F)</th></tr><tr><th>Control</th><th>Schizophrenia</th><th><i>p</i>-value<sup>a</sup></th><th>Control</th><th>Schizophrenia</th><th><i>p</i>-value<sup>a</sup></th></tr></thead><tbody><tr><td colspan="8"><strong>Primary datasets</strong></td></tr><tr><td>Blood (PBMCs)</td><td>29 HC/43 SZ</td><td>23.02 ± 4.03</td><td>23.90 ± 4.08</td><td>0.378</td><td>29/0</td><td>43/0</td><td>1</td></tr><tr><td>Olfactory epithelium</td><td>19 HC/19 SZ</td><td>39.7 ± 11.6</td><td>38.9 ± 11.4</td><td>0.829</td><td>13/6</td><td>13/6</td><td>1</td></tr><tr><td>Skin fibroblasts</td><td>20 HC/20 SZ</td><td>48.4 ± 12.2</td><td>44.6 ± 12.7</td><td>0.340</td><td>9/11</td><td>10/10</td><td>0.758</td></tr><tr><td colspan="8"><strong>Validation dataset</strong></td></tr><tr><td>Blood (whole blood)</td><td>96 HC/106 SZ</td><td>39.3 ± 14.2</td><td>39.6 ± 10.7</td><td>0.877</td><td>42/54</td><td>76/30</td><td>1 × 10<sup>-4</sup></td></tr></tbody></table>

PBMCs peripheral blood mononuclear cells, HC healthy controls, SZ individuals with schizophrenia

RAN, XPO5, NUP153, DICER1, and AGO2⁵⁰. Additionally, we included XPO1 which is involved in an alternative, noncanonical pathway⁵¹ (Fig. 1). Expression of RAN, XPO5, NUP153, and XPO1 has never been systematically explored in previous studies on psychiatric disorders although these genes are involved in miRNAs export to the cytoplasm, which constitutes an essential step in the miRNA maturation process.

## Ethical statement

All the data used in this project were acquired in previous studies, all of which conformed to ethical standards³⁶⁻⁴³,⁴⁸,⁴⁹.

## Statistical analysis

XLSTAT software (XLSTAT 2017: Data Analysis and Statistical Solution for Microsoft Excel. Addinsoft, Paris, France, 2017) was used to perform statistical analyses. For each included GEO dataset, demographic characteristics of subjects and quality data of samples in HC and SZ patient groups were compared using unpaired *t*-test (for age, postmortem interval, brain pH, and RNA integrity number), and Fisher exact test (for gender).

For each tissue, we used *shinyGEO* application to realize differential expression analysis between SZ individuals and HC⁵². *shinyGEO* is implemented using R [https://www.r-project.org/] and shiny [http://shiny.rstudio.com/]. *shinyGEO* downloads processed gene expression datasets from GEO using GEOquery package⁵³, gene expression values are log2-transformed to stabilize the variance. Descriptive Statistics of log2(candidate gene expression) values in brain and peripheral tissues are provided in Supplementary Table 3. Normal distribution was tested using Shapiro-Wilk test. For differential expression, exact *p*-values were calculated using unpaired, two-tailed *t*-tests. When a deviation from normality was detected, exact *p*-values were calculated using unpaired, two-tailed Mann-Whitney *U*-tests. In case of violation of the equal

variance assumption, exact *p*-values were calculated using unpaired, two-tailed Welch tests. The resulting *p*-values have been adjusted by the Benjamini and Hochberg's approach to control the false discovery rate. Gene expression comparisons were considered to be statistically significant for adjusted *p*-values < 0.05.

## Results

### Differential expression analysis in the brain tissues

Compared to HC, we observed distinct altered expression patterns of the miRNA BM coding genes in the brain tissues of SZ individuals with the exception of the anterior prefrontal (BA10), parietal and superior temporal (BA22) cortices in which no alterations were found. SZ individuals exhibited a set of genes significantly upregulated in the DLPFC (BA46) (XPO1 and DICER1), the associative striatum (XPO1) and in the cerebellum (DROSHA, NUP153, DICER1, and AGO2). Moreover, altered transcription of several of the candidate genes was identified in the hippocampus (DROSHA, DGCR8, RAN, XPO5, XPO1, DICER1, and AGO2). In the validation dataset derived from DLPFC (BA46) samples, we replicated DICER1 overexpression in SZ individuals vs. HC. The detailed results are provided in Fig. 2 and Supplementary Table 4.

### Differential expression analysis in the peripheral tissues

Compared to HC, distinct altered transcription patterns of the miRNA BM coding genes were identified in the peripheral tissues of SZ individuals. SZ individuals exhibited a set of differentially expressed genes in the PBMCs (DROSHA, DGCR8, XPO5, NUP153, DICER1, and AGO2) and in the olfactory epithelium (RAN, XPO1, and AGO2). In contrast, no changes were found in the skin fibroblasts. In the validation dataset derived from whole blood samples, we replicated DICER1 overexpression and DGCR8, XPO5, AGO2 decreased expression in SZ individuals vs. HC. The detailed results are provided in Fig. 3 and Supplementary Table 5.

<footnote>ªUnpaired t-tests and Fisher exact tests were conducted to assess group differences for continuous and discrete variables, respectively.</footnote>
<figure><img src="image_4.png" /></figure>

Discussion

Compared to HC, we observed altered expression pat-
terns of the miRNA BM coding genes both in brain and
peripheral tissues of SZ individuals. These patterns were
distinct between the different tissues. All the original
studies from which are derived the included datasets used
a genome-wide approach. As a principle, the expression of
all genes was analyzed, including those involved in the

miRNA BM. However, while some original studies have
reported differential expression of these genes in their
supplementary data³⁶,⁴², those results were not discussed
in the original experiments. The present study re-analyzed
the original data using a candidate-gene approach,
allowing us to extend previous knowledge on
schizophrenia-associated microRNA BM dysregulation to
other brain regions and peripheral tissues.
<figure><img src="image_5.png" /></figure>

First, we report distinct altered transcriptional patterns of the miRNA BM coding genes in four brain regions (the DLPFC, associative striatum, hippocampus, and cerebellum) of SZ individuals vs. HC. Notably, heterogeneous results have been identified both at the gene-level (some miRNA BM genes undergo significant expression changes whereas others show no alteration) and at the brain

region-level (the altered transcriptional patterns differ from one brain region to another). Such distinct abnormal transcription patterns have been previously reported in two different brain regions, namely the DLPFC (including BA9 and BA46) and the superior temporal gyrus (BA22)³⁰,³¹. The spatial heterogeneity of the observed transcriptional alterations may contribute to the distinct
abnormal expression patterns of miRNA<sup>28,30,31,54–60</sup> and subsequently, to the heterogeneous abnormal mRNA levels<sup>7,8,61</sup> (through miRNA-induced mRNA degradation) and protein levels<sup>62–64</sup> (through the interference of mRNA translation) observed in various brain regions of SZ individuals.

In the DLPFC (BA46), associative striatum and cerebellum of SZ individuals vs. HC, all the explored miRNA BM genes whose expression was altered were overexpressed, suggesting a heightened miRNA production in these brain regions. Our results are consistent with the increased expression of miRNAs previously reported in the DLPFC (BA46) of SZ individuals<sup>31</sup>. In the DLPFC, overexpression of miRNAs could account for the emergence of SZ during the brain maturation period of late adolescence. Indeed, in the DLPFC, global miRNA expression physiologically displays a reduction from adolescence, with a predominant inflexion point at 17 years<sup>65</sup>. In adolescence, overexpression of the miRNA BM may thus constitute a disruption of the posttranscriptional regulatory environment. In adulthood, persistent overexpression of miRNA BM genes may reflect immaturity of the brain tissue which is in accordance with the report that miRNAs normally enriched in infants tend to be upregulated in SZ individuals<sup>66</sup>.

To our knowledge, it is the first time that an over-expression of the miRNA biogenesis genes is reported in the associative striatum and the cerebellum of SZ indivi-duals. Since, none of the available studies exploring the cerebral expression of miRNA in SZ individuals have examined cerebellum or striatum tissues<sup>28,30,31,54–60</sup>, more studies are needed to determine if the herein reported overexpression of the miRNA BM genes is associated with a global increase in miRNA expression in these areas. In this regard, high quality brain collections are compulsory considering the limited stability and short half-life of specific brain-enriched miRNAs<sup>67</sup>. We also report an altered transcriptional pattern of miRNA BM coding genes in the hippocampus of SZ individuals. While some miRNA BM genes were overexpressed, others were underexpressed. The complexity of this altered tran-scriptional pattern does not allow for a clear hypothesis on the overall level of miRNA in this structure.

While previous studies observed aberrant transcription of the miRNA BM in the DLPFC BA46 and BA9<sup>30,31</sup>, our results expand this epigenetic disruption to subcortical structures and to the cerebellum. This is in accordance with the central role of these areas in SZ pathogenesis<sup>68</sup>. On the one hand, all these regions exert crucial roles in cognition processes<sup>46,69–71</sup>, and are considered as key regions in the pathophysiology of schizophrenia<sup>44–47</sup>. On the other hand, there is now increasing evidence that miRNAs play an important role in various aspects of synaptic plasticity<sup>21</sup>, and that the dynamic changes in

miRNA levels regulate the expression of genes involved in cognitive processes<sup>72</sup>. Disruption of the miRNA BM in brain structures involved in cognitive functions may thus participate to the cognitive impairment associated with schizophrenic disorders<sup>66,73</sup>.

In the blood compartment and olfactory epithelium of SZ individuals vs. HC, we observed two distinct altered transcriptional patterns characterized by an overall underexpression of the candidate genes (except for the overexpression of DICER1 and RAN in the blood compartment and olfactory epithelium, respectively). In contrast, no changes were found in the skin fibroblasts.

Although skin fibroblasts are considered as a promising surrogate system for the study of SZ pathogenesis<sup>74</sup>, our results suggest that they may not be affected by tran-scriptional alterations of the miRNA BM. In PBMCs, whole blood and olfactory epithelium of SZ individuals the aberrant transcription of the candidate genes is con-sistent with the previously reported altered expression of a wide range of miRNAs in peripheral blood<sup>75–77</sup>, and olfactory epithelium<sup>78</sup> of SZ individuals. However, in the present study, the transcriptional alterations observed in peripheral tissues did not reflect those identified in the brain tissues of SZ individuals (with the exception of DICER1 overexpression in the blood compartment). Such discrepancies were expected since (i) peripheral blood and olfactory epithelium have specific expression profiles, distinct from that of the brain tissue, thus, they can't be perfect surrogates for gene expression in the brain<sup>79,80</sup>, (ii) brain and peripheral tissues samples used in the present study were not derived from the same subjects and (iii) brain and peripheral tissues of SZ individuals might be affected by different alterations<sup>79</sup>. Nevertheless, such dis-crepancies does not preclude the possibility that tran-scriptional alterations observed in peripheral tissues could be used as clinical biomarkers of schizophrenia<sup>18,74–76,78,79</sup>. More studies in peripheral tissues are needed to identify effective sources of biomarkers for SZ.

Among individual genes whose expression was altered in the present study, a significant finding was the increased expression of DICER1 in the DLPFC (BA46), hippocampus, cerebellum and PBMCs of SZ individuals compared to HC. Moreover, in the blood compartment, we replicated DICER1 overexpression in the whole blood of SZ individuals vs. HC. It is noteworthy that DICER1 expression is age-dependent with a significant increase from young adulthood onward<sup>65</sup>. However, since there was no significant difference between the mean age of SZ individuals and HC in the different datasets, it is unlikely that age explains our results.

In the DLPFC (BA46), our results are consistent with two previous studies reporting a significant upregulation of DICER1 in the DLPFC (BA46 and BA9) of SZ indivi-duals from an independent collection of postmortem
brain samples³⁰,³¹. On the one hand, DICER1 is essential for neural and synaptic plasticity⁸¹. Moreover, DICER1 codes for the Dicer enzyme, which is involved in neural cell differentiation⁵⁰ and immune cell regulation⁸². On the other hand, the DICER1 overexpression observed in the present study is likely associated with a global increase in miRNA expression as reported in the DLPFC of SZ individuals³¹. Such an association between an upregulation of Dicer and a global increase in miRNA expression has been previously shown in tumorous cells⁸³. Altogether, these results suggest that DICER1 overexpression in brain tissues of SZ individuals may be associated with an increased miRNA production, leading to extensive detrimental consequences on synaptic and neural plasticity as well as on immune cell function. DICER1 overexpression may constitute a key mechanism in the SZ pathogenesis. The association between genetic polymorphisms in DICER1 and increased risk to develop SZ sustains this hypothesis²⁷,²⁸,⁸⁴,⁸⁵.

Remarkably, in the blood compartment as well, we report DICER1 overexpression in the PBMCs and whole blood of SZ individuals vs. HC. These results are consistent with two previous peripheral studies. A genome-wide significant overexpression of DICER1 was identified in the lymphoblastoid cell lines (LCL) of SZ individuals vs. HC⁸⁶. DICER1 overexpression was also reported in the whole blood of treatment-resistant SZ individuals vs. HC¹¹. In the whole blood of individuals with first episode psychosis (FEP), DICER1 overexpression may depend on the treatment status and IL-6 peripheral levels⁸⁷⁻⁸⁹. DICER1 overexpression in the blood compartment may thus be a clinically useful peripheral biomarker of SZ. More studies are needed to assess the interaction between antipsychotic treatment and IL-6/DICER1 blood expression levels.

In SZ individuals, we observed an altered expression of DROSHA and DGCR8 genes encoding proteins involved in the nuclear maturation step of miRNAs.

At the brain level, the decreased hippocampal expression of DROSHA contrasted with its upregulation in the cerebellum. These results are consistent with and extend those of two previous studies who reported DROSHA overexpression in the DLPFC (BA9) of SZ individuals, while no alteration was observed in the DLPFC (BA46) and superior temporal gyrus (BA22)³⁰,³¹. The DGCR8 hippocampal overexpression observed in the present experiment is consistent with the increased expression of DGCR8 reported in the DLPFC (BA9) and superior temporal cortex (BA22) of SZ individuals³⁰. However, we did not confirm DGCR8 overexpression in the superior temporal cortex (BA22) of SZ individuals. These discrepant results may be due to the heterogeneity of the demographic and clinical characteristics of the human samples: age, illness duration, nature, and/or severity of

symptomatology may influence the miRNA biogenesis system and thus constitutes confounding factors. While illness duration and clinical features were not available in both studies, the population presently studied was older than that studied by Beveridge et al.³⁰ (mean age ± SD; present study: SZ individuals: 72.2 ± 16.9 years/control subjects: 67.7 ± 22.2 years; Beveridge et al. study: SZ individuals: 52.7 ± 11.7 years/control subjects: 53.2 ± 11.4 years). Altogether these results suggest that the nuclear processing step of miRNAs biogenesis may be altered in various brain regions of SZ individuals. Interestingly, overexpression of DROSHA may exert detrimental effects on the miRNA production through the destabilization of DGCR8 mRNA by Drosha enzyme⁵⁰. Moreover, DGCR8 is located within the 22q11.2 region which is prone to spontaneous structural variation. 22q11.2 microdeletion (leading to decreased expression of DGCR8) is the strongest known genetic risk factor for SZ disorders⁹⁰. 22q11.2 microduplication (leading to overexpression of DGCR8) has also been recently reported in SZ individuals⁹¹ and shown to increase risk for intellectual disability and autism spectrum disorder⁹²,⁹³. DGCR8 abnormal expression may thus constitute a nonspecific risk factor for neurodevelopmental disorders.

At the peripheral level, we observed a decreased expression of DROSHA and DGCR8 in the PBMCs of SZ individuals, suggesting a reduction in miRNAs nuclear processing in the blood compartment. However, when considering previous results from whole blood samples of FEP individuals vs. HC, mixed results have been reported regarding DROSHA and DGCR8 expression⁸⁷⁻⁸⁹. Such discrepancies between PBMCs and whole blood are expected since those two tissues have distinct expression profiles⁹⁴. However, additional factors such as illness duration⁸⁷⁻⁸⁹, antipsychotic status⁸⁹, peripheral cytokine levels⁸⁸, or antipsychotic-IL-6 interaction⁸⁸ may be involved in the mixed results observed in the blood compartment.

Interestingly, we report for the first time XPO1 altered expression in SZ individuals compared to HC. In the present study, XPO1 was overexpressed in the DLPFC (BA46), the associative striatum and the hippocampus, whereas it was downregulated in the olfactory epithelium. This is coherent with previous results reporting XPO1 as a contributing factor to neurodevelopmental disorders⁹⁵.

Apart from the canonical biogenesis pathway, various alternative factors have been implicated in miRNA biogenesis⁵⁰. Notably, while the majority of premiRNAs are exported to the cytoplasm through the canonical pathway (involving exportin 5 and RAN nuclear protein, encoded by XPO5 and RAN, respectively), the exportin 1 protein (encoded by XPO1), involved in a noncanonical pathway, can export specific miRNAs to the cytoplasm⁵⁰,⁵¹. Moreover, during cellular quiescence, the canonical
miRNA biogenesis pathway is downregulated and specific miRNAs are generated by an alternative exportin 1-dependent pathway⁹⁶. In the DLPFC (BA46), associative striatum and hippocampus, our results raise for the first time the intriguing question of whether schizophrenia is associated with a shift towards the activation of a non-canonical miRNA biogenesis pathways in cerebral tissues⁹⁷. Consistently, in the hippocampus of SZ individuals, XPO1 overexpression contrasted with the decreased expression of the canonical miRNA biogenesis genes XPO5 and RAN. Intriguingly, we observed opposite transcriptional abnormalities in the olfactory epithelium (downregulation of XPO1 and overexpression of RAN) suggesting that the putative shift towards a noncanonical pathway may be restricted to cerebral tissues of SZ individuals.

In the present study, AGO2 expression was altered in opposite directions between brain and peripheral tissues of SZ individuals: it was overexpressed in the hippocampus and cerebellum, whereas its expression was decreased in the PBMCs, whole blood, and olfactory epithelium. Our results replicate and extend the decreased expression of AGO2 previously reported in the PBMCs of SZ individuals³². Further research is needed to determine if peripheral downregulation of AGO2 expression could represent a biomarker of SZ.

Recently, AGO2 has been functionally linked to deleterious stress exposure. Indeed, Bam et al. reported a decreased expression of AGO2 in the PBMCs of war veterans suffering from PTSD⁹⁸. In this latter study, AGO2 decreased expression was associated with the underexpression of numerous miRNAs targeting proinflammatory genes and lead to PTSD-associated chronic peripheral inflammation. At the brain level, animal models have shown that specific miRNAs associate with Ago2 protein in the amygdala following chronic stress⁹⁹,¹⁰⁰. Altogether, these results suggest that AGO2 may be involved in stress response mechanisms and that its altered expression may be associated to detrimental stress exposures. In the present study, traumatic events were not provided, thus we could not explore a possible link between AGO2 altered expression and exposure to stressful events. More studies are needed to explore the impact of stress on the miRNA BM.

## Limits

Interpretation of the present results is affected by limiting factors. First, brain and peripheral tissues were obtained from eight different and modest-sized SZ samples. PBMCs were collected from rather young men (mean age ± SD: 23.02 ± 4.03 for the controls and 23.90 ± 4.08 for the SZ individuals), whereas brain tissues were obtained from older men and women (Table 1). Therefore, the gene expression changes identified in the cerebral tissues may reflect the influence of age, while those

identified in the PBMCs may be gender specific. However, previous studies investigating miRNA BM expression in the cerebral cortex did not find any significant correlation between gender and gene expression levels³⁰,³¹,⁶⁵. In contrast, Beveridge et al. reported that DICER1 (but not DROSHA or DGCR8) expression increased with age⁶⁵. However, since we did not find any significant difference in age between control subjects and SZ individuals in the different datasets used in the present study (Tables 1 and 2), it is unlikely that age explain our results. Second, factors inherent in postmortem brain studies, and beyond the investigator's control, might have influenced our results. (i) Treatment data were not provided for the GEO datasets. Thus, a potential impact of antipsychotic treatment on candidate gene expression could not be ruled out. In individuals with FEP, baseline circulating IL-6 levels may modulated the gene expression response of DICER1 and DROSHA to treatment with risperidone⁸⁸. Further studies are needed to replicate these results. (ii) The other concern is the effect of brain pH on our results since we observed a significant difference in brain pH between control and SZ patient groups in the anterior PFC (BA10) and superior temporal cortex. However, the main results discussed in the present study do not derive from these samples.

This study provides evidence of a widespread transcriptional disruption of the miRNA BM both in brain and peripheral tissues of SZ individuals. In the DLPFC (BA46), associative striatum and cerebellum of SZ individuals, we observed an overexpression pattern of the candidate genes suggesting a heightened miRNA production in these brain regions. In SZ individuals, the transcriptional abnormalities were further extended to the hippocampus. These aberrant transcription patterns may contribute to SZ pathogenesis. Moreover, we observed distinct transcriptional abnormalities of the miRNA BM in peripheral tissues suggesting that SZ is a systemic disease. In SZ individuals, we finally reported a DICER1 overexpression in the hippocampus, cerebellum, and DLPFC (BA46) (consistently with two previous reports). We furthermore reported a congruent overexpression of DICER1 in the peripheral blood of two independent samples of SZ individuals. These latter results replicate two previous observations and suggest that it may represent a clinically useful peripheral marker.

## Acknowledgements

We would like to thank Jasmine Dumas and Garrett Dancik from the Department of Computer Science at Eastern Connecticut State University for the development of *shinyGEO* application and for their help in using the application. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

## Author details

¹INSERM, U1028; CNRS, UMR5292, Lyon Neuroscience Research Center, Psychiatric Disorders: from Resistance to Response Team, 69000 Lyon, France.
²University Lyon 1, 69000 Villeurbanne, France. ³Schizophrenia Expert Centre, Le Vinatier Hospital, Bron, France. ⁴Department of Old Age Psychiatry, Le Vinatier Hospital, Bron, France. ⁵Department of Genetics and Laboratory of Molecular Genetics, University Hospital, Dijon, France

**Data availability**

The data that support the findings of this study are openly available in Gene Expression Omnibus (NCBI) at https://www.ncbi.nlm.nih.gov/geo/, reference numbers, GSE17612, GEO21138, GSE21935, GSE27383, GSE35974, GSE35977, GEO38484, GSE53987, GSE62333, GSE73129.

**Conflict of interest**

The authors declare that they have no conflict of interest.

**Publisher's note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Supplementary Information** accompanies this paper at (https://doi.org/10.1038/s41398-020-01052-5).

Received: 14 March 2020 Revised: 16 September 2020 Accepted: 1 October 2020

Published online: 04 November 2020

**References**

1. Laidi, C. et al. Factors associated with direct health care costs in schizophrenia: Results from the FACE-SZ French dataset. *Eur. Neuropsychopharmacol.* **28**, 24–36 (2018).

2. Laursen, T. M., Nordentoft, M. & Mortensen, P. B. Excess early mortality in schizophrenia. *Annu. Rev. Clin. Psychol.* **10**, 425–448 (2014).

3. Leza, J. C. et al. Inflammation in schizophrenia: a question of balance. *Neurosci. Biobehav. Rev.* **55**, 612–626 (2015).

4. Nemani, K., Hosseini Ghomi, R., McCormick, B. & Fan, X. Schizophrenia and the gut-brain axis. *Prog. Neuropsychopharmacol. Biol. Psychiatry* **56**, 155–160 (2015).

5. Uher, R. Gene-environment interactions in severe mental illness. *Front. Psychiatry* **5**, 48 (2014).

6. Avramopoulos, D. Recent advances in the genetics of schizophrenia. *Mol. Neuropsychiatry* **4**, 35–51 (2018).

7. Kumarasinghe, N., Tooney, P. A. & Schall, U. Finding the needle in the haystack: a review of microarray gene expression research into schizophrenia. *Aust. N. Z. J. Psychiatry* **46**, 598–610 (2012).

8. Li, X. & Teng, S. RNA sequencing in schizophrenia. *Bioinform. Biol. Insights* **9**, 53–60 (2015).

9. Karim, S. et al. Global expression studies of schizophrenic brain: a meta-analysis study linking neurological immune system with psychological disorders. *CNS Neurol. Disord. Drug Targets* **15**, 477–488 (2016).

10. Quednow, B. B., Brzózka, M. M. & Rossner, M. J. Transcription factor 4 (TCF4) and schizophrenia: integrating the animal and the human perspective. *Cell. Mol. Life Sci.* **71**, 2815–2835 (2014).

11. Moretti, P. N. et al. Accessing gene expression in treatment-resistant schizophrenia. *Mol. Neurobiol.* **55**, 7000–7008 (2018).

12. Pries, L-K., Gülöksüz, S. & Kenis, G. DNA methylation in schizophrenia. *Adv. Exp. Med. Biol.* **978**, 211–236 (2017).

13. Thomas, E. A. Histone posttranslational modifications in schizophrenia. *Adv. Exp. Med. Biol.* **978**, 237–254 (2017).

14. Gibbons, A., Udawela, M. & Dean, B. Non-coding RNA as novel players in the pathophysiology of schizophrenia. *Noncoding RNA* **4**, 11 (2018).

15. Punzi, G., Bharadwaj, R. & Ursini, G. Neuroepigenetics of schizophrenia. *Prog. Mol. Biol. Transl. Sci.* **158**, 195–226 (2018).

16. Liu, Y. et al. Non-coding RNA dysregulation in the amygdala region of schizophrenia patients contributes to the pathogenesis of the disease. *Transl. Psychiatry* **8**, 44 (2018).

17. Alural, B., Genc, S. & Haggarty, S. J. Diagnostic and therapeutic potential of microRNAs in neuropsychiatric disorders: past, present, and future. *Prog. Neuropsychopharmacol. Biol. Psychiatry* **73**, 87–103 (2017).

18. Beveridge, N. J. & Cairns, M. J. MicroRNA dysregulation in schizophrenia. *Neurobiol. Dis.* **46**, 263–271 (2012).

19. Wakabayashi, T., Hidaka, R., Fujimaki, S., Asashima, M. & Kuwabara, T. MicroRNAs and epigenetics in adult neurogenesis. *Adv. Genet.* **86**, 27–44 (2014).

20. Rao, Y. S. & Pak, T. R. microRNAs and the adolescent brain: filling the knowledge gap. *Neurosci. Biobehav. Rev.* **70**, 313–322 (2016).

21. Ye, Y., Xu, H., Su, X. & He, X. Role of microRNA in governing synaptic plasticity. *Neural Plast.* **2016**, 4959523 (2016).

22. Esteller, M. Non-coding RNAs in human disease. *Nat. Rev. Genet.* **12**, 861–874 (2011).

23. Mendell, J. T. MicroRNAs: critical regulators of development, cellular physiology and malignancy. *Cell Cycle* **4**, 1179–1184 (2005).

24. Friedman, R. C., Farh, K. K.-H., Burge, C. B. & Bartel, D. P. Most mammalian mRNAs are conserved targets of microRNAs. *Genome Res.* **19**, 92–105 (2009).

25. Murphy, K. C. Schizophrenia and velo-cardio-facial syndrome. *Lancet* **359**, 426–430 (2002).

26. Fénelon, K. et al. Deficiency of Dgcr8, a gene disrupted by the 22q11.2 microdeletion, results in altered short-term plasticity in the prefrontal cortex. *Proc. Natl Acad. Sci. USA* **108**, 4447–4452 (2011).

27. Zhou, Y. et al. Evaluation of six SNPs of MicroRNA machinery genes and risk of schizophrenia. *J. Mol. Neurosci.* **49**, 594–599 (2013).

28. Zhang, F. et al. Converging evidence implicates the abnormal microRNA system in schizophrenia. *Schizophr. Bull.* **41**, 728–735 (2015).

29. Mellios, N. & Sur, M. The emerging role of microRNAs in schizophrenia and autism spectrum disorders. *Front. Psychiatry* **3**, 39 (2012).

30. Beveridge, N. J., Gardiner, E., Carroll, A. P., Tooney, P. A. & Cairns, M. J. Schizophrenia is associated with an increase in cortical microRNA biogenesis. *Mol. Psychiatry* **15**, 1176–1189 (2010).

31. Santarelli, D. M., Beveridge, N. J., Tooney, P. A. & Cairns, M. J. Upregulation of dicer and microRNA expression in the dorsolateral prefrontal cortex Brodmann area 46 in schizophrenia. *Biol. Psychiatry* **69**, 180–187 (2011).

32. Gardiner, E. J. et al. Gene expression analysis reveals schizophrenia-associated dysregulation of immune pathways in peripheral blood mononuclear cells. *J. Psychiatr. Res.* **47**, 425–437 (2013).

33. Barrett, T. et al. NCBI GEO: archive for functional genomics data sets-update. *Nucleic Acids Res.* **41**, D991–D995 (2013).

34. Pradervand, S. et al. Affymetrix whole-transcript human gene 1.0 ST array is highly concordant with standard 3' expression arrays. *BioTechniques* **44**, 759–762 (2008).

35. Robinson, M. D. & Speed, T. P. A comparison of Affymetrix gene expression arrays. *BMC Bioinform.* **8**, 449 (2007).

36. Lanz, T. A. et al. Postmortem transcriptional profiling reveals widespread increase in inflammation in schizophrenia: a comparison of prefrontal cortex, striatum, and hippocampus among matched tetrads of controls with subjects diagnosed with schizophrenia, bipolar or major depressive disorder. *Transl. Psychiatry* **9**, 151 (2019).

37. Maycox, P. R. et al. Analysis of gene expression in two large schizophrenia cohorts identifies multiple changes associated with nerve terminal function. *Mol. Psychiatry* **14**, 1083–1094 (2009).

38. Barnes, M. R. et al. Transcription and pathway analysis of the superior temporal cortex and anterior prefrontal cortex in schizophrenia. *J. Neurosci. Res.* **89**, 1218–1227 (2011).

39. Chen, C. et al. Two gene co-expression modules differentiate psychotics and controls. *Mol. Psychiatry* **18**, 1308–1314 (2013).

40. Chen, C. et al. The transcription factor POU3F2 regulates a gene coexpression network in brain tissue from patients with psychiatric disorders. *Sci. Transl. Med.* **10**, eaat8187 (2018).

41. van Beveren, N. J. M. et al. Marked reduction of AKT1 expression and deregulation of AKT1-associated pathways in peripheral blood mononuclear cells of schizophrenia patients. *PLoS ONE* **7**, e32618 (2012).

42. Horiuchi, Y. et al. Molecular signatures associated with cognitive deficits in schizophrenia: a study of biopsied olfactory neural epithelium. *Transl. Psychiatry* **6**, e915 (2016).

43. Cattane, N. et al. Altered gene expression in schizophrenia: findings from transcriptional signatures in fibroblasts and blood. *PLoS ONE* **10**, e0116686 (2015).

44. Grot, S. et al. Abnormal prefrontal and parietal activity linked to deficient active binding in working memory in schizophrenia. *Schizophr. Res.* **188**, 68–74 (2017).
45. McCutcheon, R. A., Abi-Dargham, A. & Howes, O. D. Schizophrenia, dopamine and the striatum: from biology to symptoms. *Trends Neurosci.* (2019). https://doi.org/10.1016/j.tins.2018.12.004.

46. Yeganeh-Doost, P., Gruber, O., Falkai, P. & Schmitt, A. The role of the cerebellum in schizophrenia: from cognition to molecular pathways. *Clinics* **66**, 71–77 (2011).

47. Nakahara, S., Matsumoto, M. & van Erp, T. G. M. Hippocampal subregion abnormalities in schizophrenia: a systematic review of structural and physiological imaging studies. *Neuropsychopharmacol. Rep.* (2018). https://doi.org/10.1002/npr2.12031.

48. Narayan, S. et al. Molecular profiles of schizophrenia in the CNS at different stages of illness. *Brain Res.* **1239**, 235–248 (2008).

49. de Jong, S. et al. A gene co-expression network in whole blood of schizophrenia patients is independent of antipsychotic-use and enriched for brain-expressed genes. *PLoS ONE* **7**, e39498 (2012).

50. Ha, M. & Kim, V. N. Regulation of microRNA biogenesis. *Nat. Rev. Mol. Cell Biol.* **15**, 509–524 (2014).

51. Muqbil, I., Bao, B., Abou-Samra, A. B., Mohammad, R. M. & Azmi, A. S. Nuclear export mediated regulation of microRNAs: potential target for drug intervention. *Curr. Drug Targets* **14**, 1094–1100 (2013).

52. Dumas, J., Gargano, M. A. & Dancik, G. M. shinyGEO: a web-based application for analyzing gene expression omnibus datasets. *Bioinformatics* **32**, 3679–3681 (2016).

53. Davis, S. & Meltzer, P. S. GEOquery: a bridge between the gene expression omnibus (GEO) and bioConductor. *Bioinformatics* **23**, 1846–1847 (2007).

54. Moreau, M. P., Bruse, S. E., David-Rus, R., Buyske, S. & Brzustowicz, L. M. Altered microRNA expression profiles in postmortem brain samples from individuals with schizophrenia and bipolar disorder. *Biol. Psychiatry* **69**, 188–193 (2011).

55. Banigan, M. G. et al. Differential expression of exosomal microRNAs in prefrontal cortices of schizophrenia and bipolar disorder patients. *PLoS ONE* **8**, e48814 (2013).

56. Beveridge, N. J. et al. Dysregulation of miRNA 181b in the temporal cortex in schizophrenia. *Hum. Mol. Genet.* **17**, 1156–1168 (2008).

57. Pietersen, C. Y. et al. Molecular profiles of pyramidal neurons in the superior temporal cortex in schizophrenia. *J. Neurogenet.* **28**, 53–69 (2014).

58. Pietersen, C. Y. et al. Molecular profiles of parvalbumin-immunoreactive neurons in the superior temporal cortex in schizophrenia. *J. Neurogenet.* **28**, 70–85 (2014).

59. Perkins, D. O. et al. microRNA expression in the prefrontal cortex of individuals with schizophrenia and schizoaffective disorder. *Genome Biol.* **8**, R27 (2007).

60. Miller, B. H. et al. MicroRNA-132 dysregulation in schizophrenia has implications for both neurodevelopment and adult brain function. *Proc. Natl Acad. Sci. USA* **109**, 3125–3130 (2012).

61. Scarr, E., Udawela, M. & Dean, B. Changed frontal pole gene expression suggest altered interplay between neurotransmitter, developmental, and inflammatory pathways in schizophrenia. *NPJ Schizophr.* **4**, 4 (2018).

62. Martins-de-Souza, D. et al. Proteome analysis of schizophrenia patients Wernicke's area reveals an energy metabolism dysregulation. *BMC Psychiatry* **9**, 17 (2009).

63. Pennington, K. et al. Prominent synaptic and metabolic abnormalities revealed by proteomic analysis of the dorsolateral prefrontal cortex in schizophrenia and bipolar disorder. *Mol. Psychiatry* **11**, 459–470 (2006). 423.

64. Clark, D., Dedova, I., Cordwell, S. & Matsumoto, I. A proteome analysis of the anterior cingulate cortex gray matter in schizophrenia. *Mol. Psychiatry* **11**, 459–470 (2006).

65. Beveridge, N. J. et al. Maturation of the human dorsolateral prefrontal cortex coincides with a dynamic shift in microRNA expression. *Schizophr. Bull.* **40**, 399–409 (2014).

66. Hu, Z. et al. Temporal dynamics of miRNAs in human DLPFC and its association with miRNA dysregulation in schizophrenia. *Transl. Psychiatry* **9**, 196 (2019).

67. Sethi, P. & Lukiw, W. J. Micro-RNA abundance and stability in human brain: specific alterations in Alzheimer's disease temporal lobe neocortex. *Neurosci. Lett.* **459**, 100–104 (2009).

68. Selemon, L. D. & Zecevic, N. Schizophrenia: a tale of two critical periods for prefrontal cortical development. *Transl. Psychiatry* **5**, e623 (2015).

69. Simpson, E. H., Kellendonk, C. & Kandel, E. A possible role for the striatum in the pathogenesis of the cognitive symptoms of schizophrenia. *Neuron* **65**, 585–596 (2010).

70. Andreasen, N. C. & Pierson, R. The role of the cerebellum in schizophrenia. *Biol. Psychiatry* **64**, 81–88 (2008).

71. Sigurdsson, T. & Duvarci, S. Hippocampal-prefrontal interactions in cognition, behavior and psychiatric disease. *Front. Syst. Neurosci.* **9**, 190 (2015).

72. Woldemichael, B. T. & Mansuy, I. M. MicroRNAs in cognition and cognitive disorders: potential for novel biomarkers and therapeutics. *Biochem. Pharmacol.* **104**, 1–7 (2016).

73. Nadim, W. D. et al. MicroRNAs in neurocognitive dysfunctions: new molecular targets for pharmacological treatments? *Curr. Neuropharmacol.* **15**, 260–275 (2017).

74. Kálmán, S., Garbett, K. A., Janka, Z. & Mirnics, K. Human dermal fibroblasts in psychiatry research. *Neuroscience* **320**, 105–121 (2016).

75. He, K., Guo, C., He, L. & Shi, Y. MiRNAs of peripheral blood as the biomarker of schizophrenia. *Hereditas* **155**, 9 (2018).

76. Lai, C.-Y. et al. Aberrant expression of microRNAs as biomarker for schizophrenia: from acute state to partial remission, and from peripheral blood to cortical tissue. *Transl. Psychiatry* **6**, e717 (2016).

77. Liu, S. et al. Diagnostic value of blood-derived microRNAs for schizophrenia: results of a meta-analysis and validation. *Sci. Rep.* **7**, 15328 (2017).

78. Mor, E. et al. MicroRNA-382 expression is elevated in the olfactory neuropeithelium of schizophrenia patients. *Neurobiol. Dis.* **55**, 1–10 (2013).

79. Cai, C. et al. Is human blood a good surrogate for brain tissue in transcriptional studies? *BMC Genomics* **11**, 589 (2010).

80. Lavoie, J., Sawa, A. & Ishizuka, K. Application of olfactory tissue and its neural progenitors to schizophrenia and psychiatric research. *Curr. Opin. Psychiatry* **30**, 176–183 (2017).

81. Davis, T. H. et al. Conditional loss of Dicer disrupts cellular and tissue morphogenesis in the cortex and hippocampus. *J. Neurosci.* **28**, 4322–4330 (2008).

82. Devasthanam, A. S. & Tomasi, T. B. Dicer in immune cell development and function. *Immunol. Invest.* **43**, 182–195 (2014).

83. Chiosea, S. et al. Up-regulation of dicer, a component of the MicroRNA machinery, in prostate adenocarcinoma. *Am. J. Pathol.* **169**, 1812–1820 (2006).

84. Xu, B. et al. Strong association of de novo copy number mutations with sporadic schizophrenia. *Nat. Genet.* **40**, 880–885 (2008).

85. Wang, Q. et al. Increased co-expression of genes harboring the damaging de novo mutations in Chinese schizophrenic patients during prenatal development. *Sci. Rep.* **5**, 18209 (2015).

86. Sanders, A. R. et al. Transcriptome study of differential expression in schizophrenia. *Hum. Mol. Genet.* **22**, 5001–5014 (2013).

87. Gouvea, E. S. et al. Gene expression alterations related to mania and psychosis in peripheral blood of patients with a first episode of psychosis. *Transl. Psychiatry* **6**, e908 (2016).

88. Noto, C. et al. Depression, cytokine, and cytokine by treatment interactions modulate gene expression in antipsychotic naïve first episode psychosis. *Mol. Neurobiol.* **53**, 5701–5709 (2016).

89. Ota, V. K. et al. Increased expression of NDEL1 and MBP genes in the peripheral blood of antipsychotic-naïve patients with first-episode psychosis. *Eur. Neuropsychopharmacol.* **25**, 2416–2425 (2015).

90. Forstner, A. J., Degenhardt, F., Schratt, G. & Nöthen, M. M. MicroRNAs as the cause of schizophrenia in 22q11.2 deletion carriers, and possible implications for idiopathic disease: a mini-review. *Front. Mol. Neurosci.* **6**, 47 (2013).

91. Rees, E. et al. Evidence that duplications of 22q11.2 protect against schizophrenia. *Mol. Psychiatry* **19**, 37–40 (2014).

92. Van Campenhout, S. et al. Microduplication 22q11.2: a description of the clinical, developmental and behavioral characteristics during childhood. *Genet. Couns.* **23**, 135–148 (2012).

93. Demily, C. et al. Additive effect of variably penetrant 22q11.2 duplication and pathogenic mutations in autism spectrum disorder: to which extent does the tree hide the forest? *J. Autism Dev. Disord.* **48**, 2886–2889 (2018).

94. Gautam, A. et al. Investigating gene expression profiles of whole blood and peripheral blood mononuclear cells using multiple collection and processing methods. *PLoS ONE* **14**, e0225137 (2019).

95. Lévy, J. et al. Molecular and clinical delineation of 2p15p16.1 microdeletion syndrome. *Am. J. Med. Genet. A* **173**, 2081–2087 (2017).

96. Martinez, I. et al. An exportin-1-dependent microRNA biogenesis pathway during human cell quiescence. *Proc. Natl Acad. Sci. USA* **114**, E4961–E4970 (2017).
97. Abdelfattah, A. M., Park, C. & Choi, M. Y. Update on non-canonical microRNAs. *Biomol. Concepts* **5**, 275–287 (2014).

98. Bam, M. et al. Decreased AGO2 and DCR1 in PBMCs from War Veterans with PTSD leads to diminished miRNA resulting in elevated inflammation. *Transl. Psychiatry* **7**, e1222 (2017).

99. Volk, N. et al. MicroRNA-19b associates with Ago2 in the amygdala following chronic stress and regulates the adrenergic receptor beta 1. *J. Neurosci.* **34**, 15070–15082 (2014).

100. Volk, N. et al. Amygdalar microRNA-15a is essential for coping with chronic stress. *Cell Rep.* **17**, 1882–1891 (2016).